OMER News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

OM

Mkt Cap

$1.17B

Volume

3.73M

Next Earnings

November 12th

Loading chart

OM

OMEROmeros Corporation

OMER

Pay with—

Available Balance0.00

OM

Mkt Cap

$1.36B

Volume

3.73M

Next Earnings

November 12th

Chart Financials Earnings News About Insider Filings

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMERPomerantz LLP is investigating potential securities fraud claims against Omeros Corporation following the company's announcement on June 26, 2026, that the European Medicines Agency's Committee for Medicinal Products for Human Use adopted a negative opinion on the marketing authorization application for narsoplimab for treating TA-TMA. The negative regulatory decision triggered a 19.12% stock price decline, falling $2.05 per share to $8.67.GlobeNewswire Inc. · Jul 28, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Omeros Corporation - OMERPomerantz LLP is investigating potential securities fraud claims against Omeros Corporation following the company's announcement of a negative opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use on its marketing authorization application for narsoplimab. The news triggered a 19.12% stock price decline on June 26, 2026.GlobeNewswire Inc. · Jul 21, 2026

Omeros Corporation Investigated by the Portnoy Law FirmThe Portnoy Law Firm has initiated an investigation into possible securities fraud at Omeros Corporation following the European Medicines Agency's negative opinion on the company's narsoplimab marketing authorization application on June 26, 2026. The negative regulatory decision triggered a 19.12% stock price decline, dropping from $10.72 to $8.67 per share. The firm is seeking to file a class action lawsuit on behalf of affected investors.GlobeNewswire Inc. · Jul 13, 2026

Heartflow vs. Omeros: Which Healthcare Innovator Stock Is a Better Buy in 2026?Heartflow, an AI-driven diagnostic platform, shows strong 40% revenue growth but faces reimbursement headwinds and remains unprofitable. Omeros is transitioning to commercial stage with its newly approved drug Yartemlea, posting early Q1 2026 revenue of $9.89 million. The article recommends Omeros as the safer bet for 2026 despite trading at a premium, citing its transition to profitability versus Heartflow's expected positive free cash flow not until 2028.The Motley Fool · Jul 8, 2026

Intellia Therapeutics vs. Omeros: Which Emerging Biotech Stock Is a Better Buy in 2026?The article compares two emerging biotech stocks: Intellia Therapeutics, which focuses on CRISPR gene-editing technology with promising Phase III trial data but significant losses and clinical risks, and Omeros, which recently achieved FDA approval for Yartemlea and posted its first commercial revenue of $9.89 million. While Intellia offers higher upside potential, Omeros is deemed the safer choice due to its transition to profitability, strong initial sales, and healthier balance sheet, despite trading at a premium valuation.The Motley Fool · Jun 20, 2026

Sagimet Biosciences Announces Appointment of Andreas Grauer, MD, as Chief Medical OfficerSagimet Biosciences appointed Dr. Andreas Grauer as Chief Medical Officer effective April 20, 2026, replacing retiring Dr. Eduardo Martins who will serve as external scientific advisor. Grauer brings over two decades of biopharmaceutical leadership experience from roles at Omeros, Federation Bio, Corcept Therapeutics, and Amgen. He received an inducement stock option grant valued at $1.34 million as part of his employment compensation.GlobeNewswire Inc. · Apr 20, 2026

Why Omeros Stock Skyrocketed TodayOmeros stock surged nearly 76% after receiving FDA approval for Yartemlea, a treatment for TA-TMA (hematopoietic stem cell transplant-associated thrombotic microangiopathy), a potentially fatal complication from stem cell transplants. This is the first and only FDA-approved treatment for this indication. The company plans to launch the drug in January 2026 and has established billing codes and patient support programs.The Motley Fool · Dec 24, 2025

Novo Nordisk's sales increased by 12% in Danish kroner and by 15% at CER in the first nine months of 2025; R&D pipeline progress continuesNovo Nordisk reported 12% sales growth in Q3 2025, with strong performance in Obesity and Diabetes care. The company is undergoing a transformation, incurring restructuring costs, and adjusting growth expectations for GLP-1 treatments.GlobeNewswire Inc. · Nov 5, 2025

Breakout Momentum Plays You Need to Know AboutThe article explores three potential momentum investment opportunities in biotech and battery technology sectors: uniQure, Omeros, and Stardust Power, highlighting their recent developments, financial positions, and analyst expectations.Investing.com · Oct 23, 2025

Complement 3 Glomerulopathy Market Poised for Phenomenal Expansion at a CAGR of 37.2% During the Forecast Period (2025–2034) Owing to the Launch of Promising Therapies Targeting C3, C5, MASP-3, and RNAi | DelveInsightThe complement 3 glomerulopathy market is projected to grow at a 37.2% CAGR from 2025-2034, driven by increasing disease awareness, advances in complement pathway research, and emerging targeted therapies targeting novel complement mechanisms.GlobeNewswire Inc. · Oct 22, 2025

to start trading

OM

OMEROmeros Corporation

OMER

Pay with—

Available Balance0.00

Your PositionYou don't own any OMER yet.

Related Tickers

Earnings